The FDA said its investigation shows that only the two recalled lots were potentially contaminated, and no adverse event reports have been received.
The agency said that administering dexmedetomidine with trace amounts of lidocaine to a patient could cause anaphylaxis, which can be life-threatening.
Read the FDA’s full news release here.
More articles on pharmacy:
NIH updates remdesivir treatment guidelines
J&J to start human trials for COVID-19 vaccine this week
Growing number of polls find Americans hesitant about getting a future COVID-19 vaccine
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.